-- MediSwitch Drug Interactions Import (Part 1/112)
DROP TABLE IF EXISTS drug_interactions;
CREATE TABLE drug_interactions (
    id INTEGER PRIMARY KEY AUTOINCREMENT,
    med_id INTEGER,
    interaction_drug_name TEXT,
    interaction_dailymed_id TEXT,
    severity TEXT,
    description TEXT,
    source TEXT,
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21043, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(14093, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(13562, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(21000, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(20999, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(22829, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(20998, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(22828, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(21012, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(6603, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(14094, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(21001, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(20997, 'drug_class', 'N/A', 'minor', 'Drug Interactions Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION ). Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used. Isoflurane is similar to sevofl', 'DailyMed'),
(28018, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1633, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28027, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28028, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(14525, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1075, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1631, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28020, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28017, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1071, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1632, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(15164, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28019, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28023, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(14005, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(11259, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(11268, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28025, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1073, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1070, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(11270, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28026, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1064, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(11241, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(11256, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28033, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(20503, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(14528, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(28021, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(14004, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1067, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(1068, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(27762, 'drug_class', 'N/A', 'severe', 'Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS).Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clon', 'DailyMed'),
(27450, 'drug_class', 'N/A', 'minor', 'Drug Interactions Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration. Chlorthalidone and related drugs may increase the responsiveness to tuboc', 'DailyMed'),
(16649, 'drug_class', 'N/A', 'minor', 'Drug Interactions Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration. Chlorthalidone and related drugs may increase the responsiveness to tuboc', 'DailyMed'),
(27451, 'drug_class', 'N/A', 'minor', 'Drug Interactions Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration. Chlorthalidone and related drugs may increase the responsiveness to tuboc', 'DailyMed'),
(24090, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27601, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18019, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1246, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20468, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13254, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30949, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12863, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23131, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17373, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14810, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13296, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(9993, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8196, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2269, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12838, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(9981, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(4877, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29120, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(11528, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1389, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5984, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27294, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29949, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(33665, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1236, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22322, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13614, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17736, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1382, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6524, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(11925, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5989, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6491, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12860, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15758, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2089, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2364, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29943, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6153, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29936, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30243, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2090, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25753, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29741, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12049, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10879, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14895, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2318, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22488, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31505, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23257, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15704, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13048, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26511, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6634, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1113, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2919, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(4625, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32067, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6158, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25066, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26794, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(16887, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1391, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17376, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20315, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(11387, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(9575, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3327, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27600, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27253, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13238, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18844, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20610, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(4096, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22955, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25825, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13295, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22162, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15703, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23369, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20283, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31587, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(16888, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31838, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2962, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22411, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5143, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29165, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(11525, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18009, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31020, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12312, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23212, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14849, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20227, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13371, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1720, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15306, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7343, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1770, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22106, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26274, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15922, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27313, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6573, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15925, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26908, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18741, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30909, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2304, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15866, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32993, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7706, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23819, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32340, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(33544, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32063, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15447, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25224, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29639, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17135, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2728, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(9542, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24671, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3591, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23250, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7465, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18119, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31797, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6156, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1884, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8920, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(775, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(28213, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3503, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5681, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3736, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13119, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24608, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8638, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8639, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15867, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13882, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(4129, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(28700, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(16140, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23921, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8242, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4806, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32473, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17340, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7046, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25409, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2061, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14809, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17737, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(16029, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29929, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18858, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32584, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18399, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31443, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30838, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(28603, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27472, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5982, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20267, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15712, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(9012, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(21445, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(23922, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20264, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15657, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8824, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14865, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1946, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32490, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(16920, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(153, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3368, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29225, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18256, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32785, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14852, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10353, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1515, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10769, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32524, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14851, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30454, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3055, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30152, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22293, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26373, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7381, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3817, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7860, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27110, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29962, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26525, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5941, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17214, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29658, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31330, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32791, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7619, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15317, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7035, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20470, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10791, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25725, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5983, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20054, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15614, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15615, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27103, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31788, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20282, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17698, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(19770, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15616, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(21190, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(29572, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20794, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25408, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12855, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(33170, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26524, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12297, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10340, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30470, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32337, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(17589, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15428, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26793, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25726, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20066, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2479, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31954, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(33049, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(21426, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30259, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14896, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22765, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(13361, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26245, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32110, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15924, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(16910, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22975, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14458, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12852, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(7034, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(10546, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(19461, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15386, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32158, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18712, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24733, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15785, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12851, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24533, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22327, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15733, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26523, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31787, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20438, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15075, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24532, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(4138, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6767, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24010, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25303, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32061, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30258, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22764, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12839, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(21512, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25752, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26324, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30351, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15429, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26791, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22046, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24936, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27102, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(14266, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25247, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(31397, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(19990, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22880, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26349, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3948, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32065, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3504, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(22763, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30615, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20426, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2455, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1848, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(1581, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(19045, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15869, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(25302, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8843, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(27599, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8046, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(5945, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3195, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15055, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15722, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(18219, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(2689, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(3406, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(30568, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20303, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15427, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(20598, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15168, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(12657, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(26253, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6183, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15876, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(6089, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(8842, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(15050, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(32103, 'miconazole nitrate, zinc oxide, white petrolatum', 'N/A', 'minor', 'The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.', 'DailyMed'),
(24090, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6657, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2124, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17669, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29617, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29069, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32344, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20468, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20109, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1820, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17569, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27062, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20492, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30386, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25501, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9842, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(213, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11337, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7348, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22543, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10096, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(14318, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4523, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21942, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(411, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(520, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28602, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10559, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21775, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15731, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25945, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27628, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25751, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15269, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(934, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(373, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22869, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9387, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12976, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4877, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3792, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31969, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29879, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21508, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27418, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30652, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20041, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30524, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22939, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21062, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22540, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33487, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18932, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26390, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31683, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6387, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8830, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17717, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25864, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6396, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5959, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8348, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3896, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32514, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26953, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13142, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16786, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21343, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26872, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7622, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11296, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4780, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14337, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4929, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7720, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24296, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5123, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24435, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25027, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11935, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15270, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19125, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5989, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25929, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24298, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2814, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14909, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5972, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25878, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5995, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1765, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32536, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24710, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32055, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8220, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(905, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24744, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24224, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16682, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18718, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32176, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32197, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13163, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18859, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14436, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32126, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21278, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(200, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32022, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22185, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25026, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32154, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27432, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12263, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18229, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28820, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(462, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9553, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19319, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2482, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26511, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(24371, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(218, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6634, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13908, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31678, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30335, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18717, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(362, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3192, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2919, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15076, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4600, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30876, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30554, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20097, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1778, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26435, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4574, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1997, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33341, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4954, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32784, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24294, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13809, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32336, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17376, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2057, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9575, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32855, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26676, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27626, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10041, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16980, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27253, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29634, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9852, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19685, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16981, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30595, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9682, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7298, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9256, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30099, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1640, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30826, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25616, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19126, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8305, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3069, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32767, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13522, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19991, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9917, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28185, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10161, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24633, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9227, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31390, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26022, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6114, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23615, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15773, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22537, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13801, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15509, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17837, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30945, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27657, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25041, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26434, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9325, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19594, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5751, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24623, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5317, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27295, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11934, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31795, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14649, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1720, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13345, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30523, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22534, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13580, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31780, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7528, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27629, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22875, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17131, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12027, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21342, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6525, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29817, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15772, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1326, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6805, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13879, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14605, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33453, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18741, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4846, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6612, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26882, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6813, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11384, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6981, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3944, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9347, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23144, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32817, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6121, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16534, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30394, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2728, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25763, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28709, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17462, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19318, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30555, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17760, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15271, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11305, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32011, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28784, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17512, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15391, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32532, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7804, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29105, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31743, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18921, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26204, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33304, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27619, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9163, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20437, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23614, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19995, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26801, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27621, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21145, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25870, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33570, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31926, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32692, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20288, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24786, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26070, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16226, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9500, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33261, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4471, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11807, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23166, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14463, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26700, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8218, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30391, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3263, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31473, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25016, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22384, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24297, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33343, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32693, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33169, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30880, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12065, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1889, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28214, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31623, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(330, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1946, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16987, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9332, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32998, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14838, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17774, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3368, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2544, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14407, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1418, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22242, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6407, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30364, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10353, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32927, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32585, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3692, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30098, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7803, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22241, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3116, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19057, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29880, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11557, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2815, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22175, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1112, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3309, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(17433, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8015, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5088, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10972, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4127, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22868, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31308, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4759, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13513, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4881, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22536, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29685, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30879, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12068, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7658, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29962, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31442, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1666, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18672, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9331, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24201, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18188, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23740, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4261, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32388, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6152, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18485, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4722, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13696, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17080, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22972, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10510, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28783, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20470, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17838, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28517, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13539, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18950, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4185, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3408, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28958, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32194, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11958, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27103, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1520, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31359, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28782, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18626, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25617, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28957, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31615, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23992, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17248, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27228, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8462, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20010, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17088, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27656, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32306, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16533, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18995, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33216, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13810, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20496, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21585, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(412, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7759, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15945, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21344, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18220, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25618, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3898, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13281, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28589, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15770, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32228, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21188, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17550, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33215, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13361, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7278, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27121, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4493, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(19427, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5483, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29795, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26051, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3085, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6637, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27655, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5991, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28821, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20531, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6972, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22413, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25950, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25944, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26087, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31138, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27618, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(15923, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24295, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33189, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20495, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6071, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21456, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4093, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4791, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28968, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18294, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7045, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17130, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31879, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30393, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28997, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27767, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20494, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25752, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22541, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30756, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(544, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22806, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16474, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8327, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27919, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31151, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8259, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16971, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3238, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33260, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(27620, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12885, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32431, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24247, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22131, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25247, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2811, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29358, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10523, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(14421, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1512, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12237, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1452, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30566, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29687, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5985, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32869, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8393, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(912, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26021, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21790, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25028, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3683, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31188, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21061, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31972, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28272, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25060, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(558, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17811, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6481, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29635, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21146, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15538, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7319, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1600, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18258, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4697, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12581, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2252, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(20598, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24204, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4268, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22007, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30336, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6323, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18829, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22626, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31189, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8842, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(32402, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29796, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26298, 'lidocaine hydrochloride, menthol', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs: Lidotral 5% with Menthol Spray should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Lidotral 5% with Menthol Spray is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15153, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(15153, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(15153, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(15153, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(15153, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(15153, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(15153, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(15153, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(15153, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(15153, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(15153, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(15153, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(15153, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(15153, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(15153, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(15153, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(15153, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(15153, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(15153, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(15153, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(15153, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(15153, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(15153, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(15153, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(15153, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(15153, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(15153, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(15153, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(15153, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(15153, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(15153, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(15153, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(15153, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(15153, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(15153, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(15153, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(15153, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(15153, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(15153, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(15153, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(15153, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(15153, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(15153, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(15153, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(15153, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(15153, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(15153, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(15153, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(15153, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(15153, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(15153, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(15153, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(15153, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(15153, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(15153, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(15153, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(15153, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(15153, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(15153, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(15153, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(15153, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(15153, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(15153, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(15153, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(15153, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(15153, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(15153, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(15153, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(15153, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(15153, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(15153, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(15153, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(15153, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(15153, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(15153, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(15153, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(15153, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(15153, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(15153, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(15153, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(15153, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(15153, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(15153, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(15153, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(15153, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(15153, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(15153, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(15153, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(15153, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(15153, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(15153, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15153, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(15153, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(15153, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(15153, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(15153, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(15153, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(15153, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(15153, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(15153, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(15153, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(15153, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(15153, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(15153, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(15153, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15153, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(15153, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(15153, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(15153, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(15153, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(15153, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(15153, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(15153, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15153, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(15153, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(15153, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(15153, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(15153, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(15153, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(15153, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(15153, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(15153, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(15153, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(15153, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(15153, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(15153, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(15153, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(15153, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(15153, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(15153, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(15153, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(15153, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(15153, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(15153, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(15153, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(15153, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(15153, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(15153, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(15153, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(15153, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(15153, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(15153, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(15153, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(15153, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(15153, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(15153, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(15153, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(15153, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(15153, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(15153, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(15153, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(15153, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(15153, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(15153, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(15153, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(15153, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(15153, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(15153, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(15153, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(15153, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(15153, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(15153, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(15153, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(15153, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(15153, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(15153, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(15153, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(15153, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(15153, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(15153, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(15153, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(15153, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(15153, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(15153, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(15153, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(15153, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(15153, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(15153, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(15153, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(15153, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(15153, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(15153, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(15153, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(15153, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(15153, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(15153, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(15153, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(15153, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(15153, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(15153, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(15153, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(15153, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(15153, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(15153, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15153, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(15153, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(15153, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(15153, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(15153, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(15153, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(15153, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(18984, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(18984, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(18984, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(18984, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(18984, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(18984, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(18984, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(18984, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(18984, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(18984, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(18984, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(18984, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(18984, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(18984, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(18984, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(18984, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18984, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18984, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(18984, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(18984, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(18984, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(18984, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(18984, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(18984, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(18984, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(18984, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(18984, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(18984, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(18984, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(18984, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(18984, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(18984, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(18984, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(18984, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(18984, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(18984, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(18984, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(18984, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(18984, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(18984, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(18984, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(18984, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(18984, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(18984, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(18984, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(18984, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(18984, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(18984, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(18984, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(18984, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(18984, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(18984, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(18984, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(18984, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(18984, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(18984, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(18984, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(18984, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(18984, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(18984, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(18984, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(18984, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(18984, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(18984, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(18984, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(18984, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(18984, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(18984, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(18984, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(18984, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(18984, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(18984, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(18984, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(18984, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(18984, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(18984, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(18984, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(18984, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(18984, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(18984, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18984, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(18984, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(18984, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(18984, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(18984, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(18984, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(18984, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(18984, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18984, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(18984, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(18984, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18984, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(18984, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18984, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(18984, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(18984, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(18984, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(18984, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(18984, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(18984, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(18984, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18984, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(18984, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(18984, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(18984, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18984, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(18984, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(18984, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(18984, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(18984, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(18984, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(18984, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(18984, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18984, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18984, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(18984, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(18984, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(18984, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(18984, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(18984, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(18984, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(18984, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(18984, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(18984, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(18984, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(18984, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(18984, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(18984, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(18984, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18984, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(18984, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(18984, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(18984, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(18984, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(18984, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(18984, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(18984, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(18984, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(18984, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(18984, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(18984, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(18984, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(18984, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(18984, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(18984, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(18984, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(18984, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(18984, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(18984, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(18984, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(18984, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18984, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18984, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(18984, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(18984, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(18984, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(18984, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(18984, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(18984, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(18984, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(18984, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(18984, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(18984, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(18984, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(18984, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(18984, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(18984, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(18984, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(18984, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(18984, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(18984, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(18984, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(18984, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(18984, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(18984, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(18984, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(18984, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(18984, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(18984, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(18984, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(18984, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(18984, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(18984, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(18984, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(18984, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(18984, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(18984, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(18984, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(18984, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18984, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(18984, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(18984, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(18984, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(18984, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18984, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(18984, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(18984, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(18984, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18984, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(18984, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(18984, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(32046, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(32046, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(32046, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(32046, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(32046, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(32046, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(32046, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(32046, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(32046, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(32046, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(32046, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(32046, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(32046, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(32046, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(32046, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(32046, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(32046, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(32046, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(32046, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(32046, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(32046, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(32046, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(32046, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(32046, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(32046, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(32046, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(32046, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(32046, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(32046, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(32046, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(32046, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(32046, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(32046, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(32046, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(32046, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(32046, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(32046, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(32046, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(32046, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(32046, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(32046, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(32046, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(32046, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(32046, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(32046, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(32046, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(32046, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(32046, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(32046, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(32046, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(32046, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(32046, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(32046, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(32046, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(32046, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(32046, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(32046, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(32046, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(32046, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(32046, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(32046, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(32046, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(32046, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(32046, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(32046, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(32046, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(32046, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(32046, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(32046, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(32046, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(32046, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(32046, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(32046, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(32046, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(32046, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(32046, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(32046, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(32046, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(32046, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(32046, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(32046, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(32046, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(32046, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(32046, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(32046, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(32046, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(32046, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(32046, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(32046, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(32046, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(32046, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32046, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(32046, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(32046, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(32046, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(32046, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(32046, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(32046, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(32046, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(32046, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(32046, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(32046, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(32046, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(32046, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(32046, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32046, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(32046, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(32046, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(32046, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(32046, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(32046, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(32046, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(32046, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(32046, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(32046, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(32046, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(32046, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(32046, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(32046, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(32046, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(32046, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(32046, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(32046, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(32046, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(32046, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(32046, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(32046, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(32046, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(32046, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(32046, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(32046, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(32046, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(32046, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(32046, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(32046, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(32046, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(32046, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(32046, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(32046, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(32046, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(32046, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(32046, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(32046, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(32046, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(32046, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(32046, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(32046, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(32046, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(32046, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(32046, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(32046, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(32046, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(32046, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(32046, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(32046, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(32046, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(32046, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(32046, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(32046, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(32046, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(32046, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(32046, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(32046, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(32046, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(32046, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(32046, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(32046, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(32046, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(32046, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(32046, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(32046, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(32046, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(32046, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(32046, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(32046, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(32046, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(32046, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(32046, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(32046, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(32046, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(32046, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(32046, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(32046, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(32046, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(32046, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(32046, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(32046, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(32046, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(32046, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(32046, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(32046, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(32046, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(32046, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(32046, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32046, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(32046, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(32046, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(32046, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(32046, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(32046, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(32046, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(13438, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(13438, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(13438, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(13438, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(13438, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(13438, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(13438, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(13438, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(13438, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(13438, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(13438, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(13438, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(13438, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(13438, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(13438, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(13438, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13438, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(13438, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(13438, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(13438, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(13438, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(13438, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(13438, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(13438, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(13438, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(13438, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(13438, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(13438, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(13438, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13438, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(13438, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(13438, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(13438, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(13438, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(13438, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(13438, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(13438, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(13438, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(13438, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(13438, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(13438, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(13438, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(13438, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(13438, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(13438, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(13438, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(13438, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(13438, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(13438, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(13438, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(13438, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(13438, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(13438, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(13438, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(13438, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(13438, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(13438, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(13438, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(13438, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(13438, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(13438, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(13438, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(13438, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(13438, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(13438, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(13438, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(13438, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(13438, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(13438, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(13438, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(13438, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(13438, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(13438, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(13438, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(13438, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13438, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(13438, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(13438, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(13438, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(13438, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13438, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(13438, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(13438, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13438, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(13438, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(13438, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(13438, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(13438, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(13438, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(13438, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(13438, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(13438, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(13438, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13438, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(13438, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(13438, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(13438, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(13438, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(13438, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(13438, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13438, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(13438, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(13438, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(13438, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(13438, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(13438, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(13438, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(13438, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(13438, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(13438, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(13438, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(13438, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(13438, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(13438, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13438, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(13438, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(13438, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13438, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(13438, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(13438, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(13438, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(13438, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(13438, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(13438, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(13438, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(13438, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(13438, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(13438, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(13438, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(13438, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(13438, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(13438, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(13438, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(13438, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(13438, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(13438, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(13438, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(13438, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(13438, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(13438, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(13438, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(13438, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(13438, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(13438, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(13438, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(13438, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(13438, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(13438, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(13438, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(13438, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(13438, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(13438, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(13438, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(13438, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(13438, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(13438, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(13438, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(13438, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(13438, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(13438, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(13438, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13438, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(13438, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(13438, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13438, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(13438, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(13438, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(13438, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(13438, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(13438, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(13438, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(13438, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(13438, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(13438, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(13438, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13438, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(13438, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(13438, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(13438, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(13438, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(13438, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(13438, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(13438, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(13438, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(13438, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(13438, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(13438, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(13438, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(13438, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(13438, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13438, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(13438, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(13438, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(13438, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(13438, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(13438, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(13438, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(13438, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(13438, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13438, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(13438, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(13438, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(23952, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(23952, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(23952, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(23952, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(23952, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(23952, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(23952, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(23952, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(23952, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(23952, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(23952, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(23952, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(23952, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(23952, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(23952, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(23952, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23952, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(23952, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(23952, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(23952, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(23952, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(23952, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(23952, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(23952, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(23952, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(23952, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(23952, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(23952, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(23952, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(23952, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(23952, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(23952, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(23952, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(23952, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23952, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(23952, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(23952, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(23952, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(23952, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(23952, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(23952, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(23952, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(23952, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(23952, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(23952, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(23952, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(23952, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(23952, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(23952, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(23952, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(23952, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(23952, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(23952, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(23952, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(23952, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(23952, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(23952, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(23952, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(23952, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(23952, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(23952, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(23952, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(23952, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(23952, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(23952, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(23952, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(23952, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(23952, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(23952, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(23952, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(23952, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(23952, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(23952, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(23952, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(23952, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23952, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(23952, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(23952, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(23952, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(23952, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23952, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(23952, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(23952, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23952, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(23952, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(23952, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(23952, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(23952, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(23952, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(23952, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(23952, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(23952, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(23952, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23952, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23952, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(23952, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(23952, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(23952, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(23952, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(23952, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(23952, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23952, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(23952, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(23952, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(23952, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23952, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(23952, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(23952, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(23952, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(23952, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(23952, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23952, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(23952, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(23952, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23952, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(23952, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23952, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(23952, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(23952, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(23952, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(23952, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(23952, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(23952, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(23952, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(23952, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(23952, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(23952, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(23952, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(23952, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(23952, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(23952, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(23952, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(23952, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(23952, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(23952, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(23952, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(23952, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(23952, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(23952, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(23952, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(23952, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(23952, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(23952, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(23952, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(23952, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(23952, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(23952, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(23952, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(23952, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(23952, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(23952, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(23952, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23952, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(23952, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(23952, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(23952, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(23952, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(23952, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(23952, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(23952, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(23952, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(23952, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(23952, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(23952, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(23952, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(23952, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23952, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(23952, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(23952, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(23952, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(23952, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(23952, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(23952, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(23952, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(23952, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23952, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(23952, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(23952, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(23952, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(23952, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(23952, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(23952, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(23952, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(23952, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(23952, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(23952, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(23952, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(23952, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(23952, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(23952, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23952, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(23952, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(23952, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(23952, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(23952, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(23952, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(23952, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(23952, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(23952, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23952, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(23952, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(23952, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(33613, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(33613, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(33613, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(33613, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(33613, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(33613, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(33613, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(33613, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(33613, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(33613, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(33613, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(33613, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(33613, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(33613, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(33613, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(33613, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(33613, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(33613, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(33613, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(33613, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(33613, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(33613, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(33613, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(33613, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(33613, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(33613, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(33613, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(33613, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(33613, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(33613, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(33613, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(33613, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(33613, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(33613, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(33613, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(33613, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(33613, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(33613, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(33613, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(33613, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(33613, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(33613, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(33613, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(33613, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(33613, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(33613, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(33613, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(33613, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(33613, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(33613, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(33613, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(33613, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(33613, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(33613, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(33613, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(33613, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(33613, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(33613, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(33613, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(33613, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(33613, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(33613, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(33613, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(33613, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(33613, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(33613, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(33613, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(33613, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(33613, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(33613, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(33613, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(33613, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(33613, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(33613, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(33613, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(33613, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(33613, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(33613, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(33613, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(33613, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(33613, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(33613, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(33613, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(33613, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(33613, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(33613, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(33613, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(33613, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(33613, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(33613, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(33613, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(33613, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(33613, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(33613, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(33613, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(33613, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(33613, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(33613, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(33613, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(33613, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(33613, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(33613, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(33613, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(33613, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(33613, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(33613, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(33613, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(33613, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(33613, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(33613, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(33613, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(33613, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(33613, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(33613, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(33613, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(33613, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(33613, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(33613, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(33613, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(33613, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(33613, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(33613, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(33613, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(33613, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(33613, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(33613, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(33613, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(33613, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(33613, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(33613, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(33613, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(33613, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(33613, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(33613, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(33613, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(33613, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(33613, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(33613, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(33613, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(33613, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(33613, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(33613, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(33613, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(33613, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(33613, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(33613, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(33613, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(33613, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(33613, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(33613, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(33613, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(33613, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(33613, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(33613, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(33613, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(33613, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(33613, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(33613, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(33613, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(33613, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(33613, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(33613, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(33613, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(33613, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(33613, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(33613, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(33613, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(33613, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(33613, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(33613, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(33613, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(33613, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(33613, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(33613, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(33613, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(33613, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(33613, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(33613, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(33613, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(33613, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(33613, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(33613, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(33613, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(33613, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(33613, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(33613, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(33613, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(33613, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(33613, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(33613, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(33613, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(33613, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33613, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(33613, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(33613, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(33613, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(33613, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(33613, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(33613, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(33613, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(33613, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(33613, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(1584, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(1584, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(1584, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(1584, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(1584, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(1584, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(1584, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(1584, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(1584, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(1584, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(1584, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(1584, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(1584, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(1584, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(1584, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(1584, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1584, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(1584, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(1584, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(1584, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(1584, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(1584, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(1584, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(1584, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(1584, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(1584, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(1584, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(1584, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(1584, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(1584, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(1584, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(1584, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(1584, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(1584, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(1584, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(1584, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(1584, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(1584, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(1584, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(1584, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(1584, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(1584, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(1584, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(1584, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(1584, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(1584, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(1584, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(1584, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(1584, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(1584, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed'),
(1584, 'omeprazole, sodium bicarbonate', 'N/A', 'major', 'Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if g', 'DailyMed'),
(1584, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.', 'DailyMed'),
(1584, 'carbidopa, levodopa and entacapone', 'N/A', 'minor', 'Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone.', 'DailyMed'),
(1584, 'captorpil', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(1584, 'fosinopril sodium', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'losartan potatssium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(1584, 'ketoconazole', 'N/A', 'major', 'Alfentanil, fentanyl, sulfentanil Indinavir, saquinavir Amlodipine, felodipine, nicardipine, nifedipine Methylprednisolone Bosentan Rifabutin Buspirone Sildenafil Busulfan Sirolimus (co-administration not recommended) Carbamazepine Tacrolimus Cilostazol Telithromycin Cyclosporine Tolterodine Digoxin Trimetrexate Docetaxel, paclitaxel Verapamil Oral anti-coagulants Vinca alkaloids (vincristine, - vinblastine, vinorelbine) Table 2. Buspirone Concomitant administration of buspirone with ketoconazole may result in significant increases in plasma concentrations of buspirone. When administered with ketoconazole tablets, a low initial dose of buspirone with subsequent dosage adjustment based on clinical assessment is recommended.', 'DailyMed'),
(1584, 'renagel', 'N/A', 'minor', '7 DRUG INTERACTIONS Renagel has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron. (7.1) In normal volunteer studies, sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol, and iron. 7.6 Iron In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate tablet.', 'DailyMed'),
(1584, 'dual-iron', 'N/A', 'minor', 'DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(1584, 'quinapril hydrochloride', 'N/A', 'moderate', 'If concomitant therapy of quinapril hydrochloride tablets with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see ).', 'DailyMed'),
(1584, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Sedative/hypnotics: Benzodiazepines:e.g.Parenterally administered midazolamclorazepatediazepamestazolamflurazepambuspironezolpidem  sedatives/hypnotics Concomitant use of parenteral midazolam with STRIBILD may increase plasma concentrations of midazolam.', 'DailyMed'),
(1584, 'mirtazapine', 'N/A', 'minor', 'Patients should be made aware of a potential increased risk for serotonin syndrome if concomitant use of mirtazapine tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St.', 'DailyMed'),
(1584, 'pantoprazole', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(1584, 'amlodipine and valsartan', 'N/A', 'minor', 'Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'omeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, iron salts and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(1584, 'doxycycline tablets and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(1584, 'doxycycline tablets  and advanced acne wash', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(1584, 'carbamazepine', 'N/A', 'minor', 'Agents that have been found, or are expected to have decreased plasma levels in the presence of carbamazepine due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(5), valproate, warfarin(6), nefazodone, ziprasidone, and zonisamide.', 'DailyMed'),
(1584, 'doxycycline monohydrate', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(1584, 'sevelamer carbonate', 'N/A', 'minor', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations CiprofloxacinMycophenolate mofetil Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer During postmarketing experience, cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.', 'DailyMed'),
(1584, 'itraconazole', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(1584, 'demeclocycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.', 'DailyMed'),
(1584, 'esomeprazole strontium', 'N/A', 'moderate', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Antiretroviral Drugs: Use with atazanavir and nelfinavir is not recommended; if saquinavir is used with esomeprazole strontium, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil).', 'DailyMed'),
(1584, 'rabeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'omeprazole sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such a digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(1584, 'carbidopa', 'N/A', 'moderate', 'Carbidopa and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(1584, 'moexipril hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'prexxartan', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., hepari', 'DailyMed'),
(1584, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'aspirin and omeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'sertraline hydrochloride', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'trandolapril tablets', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'amlodipine and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'omeprazole and sodium bicarbonate', 'N/A', 'minor', '7 DRUG INTERACTIONS May interfere with drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, erlotinib, digoxin, and mycophenolate mofetil) (7.1) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium bicarbonate can prolong their elimination. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(1584, 'pantoprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'ritonavir', 'N/A', 'minor', 'Sedative/hypnotics:buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(1584, 'diphenoxylate hydrochloride and atropine sulfate', 'N/A', 'minor', 'Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate tablets with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).', 'DailyMed'),
(1584, 'dolutegravir sodium', 'N/A', 'minor', '(7.2, 7.3) TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. Oral calcium or iron supplements, including multivitamins containing calcium or iron a Dolutegravir Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(1584, 'potassium chloride', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(1584, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(1584, 'moxifloxacin hydrochloride tablets, 400 mg', 'N/A', 'minor', 'Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin hydrochloride, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1584, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'busulfan', 'N/A', 'minor', '7 DRUG INTERACTIONS Drugs that Decrease busulfan Clearance: Metronidazole, itraconazole, Iron chelating agent acetaminophen. Discontinue iron chelating agents well in advance of administration of busulfan to avoid increased exposure to busulfan.', 'DailyMed'),
(1584, 'perindopril arginine and amlodipine besylate', 'N/A', 'minor', 'Potassium Supplements and Potassium-Sparing Diuretics: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements, or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules', 'N/A', 'minor', 'Antacids, Multivitamins, or Dairy Products The absorption of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(1584, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'norvir', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(1584, 'lisinopril and hydrochlorothiazide tablets', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'deferiprone', 'N/A', 'minor', '(7.2) Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between administration of FERRIPROX and other medications (e.g., antacids) or supplements containing these polyvalent cations [see Dosage and Administration (2.2)].', 'DailyMed'),
(1584, 'sevelamer carbonate for oral suspension', 'N/A', 'major', 'Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer  For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7)  Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, ir', 'DailyMed'),
(1584, 'sodium sulfate, potassium sulfate, magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'carbidopa tablets', 'N/A', 'moderate', 'Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(1584, 'risedronate sodium', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(1584, 'trientine hydrochloride', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and Syprine each inhibit absorption of the other, two hours should elapse between administration of Syprine and iron.', 'DailyMed'),
(1584, 'trientine', 'N/A', 'minor', 'However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilsons disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.', 'DailyMed'),
(1584, 'risedronate sodium hemi-pentahydrate', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium delayed-release tablets were administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3 ) ]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium delayed-release tablets and should not be taken together.', 'DailyMed'),
(1584, 'deferasirox', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [ see Clinical Pharmacology (12.3)].', 'DailyMed'),
(1584, 'olmesartan medoxomil', 'N/A', 'minor', '7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium.', 'DailyMed'),
(1584, 'moxifloxacin', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1584, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(1584, 'iron sucrose', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(1584, 'baloxavir marboxil', 'N/A', 'minor', '7 DRUG INTERACTIONS Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).', 'DailyMed'),
(1584, 'felodipine extended-release tablets', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(1584, 'paroxetine', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(1584, 'paroxetine hydrochloride', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'paclitaxel', 'N/A', 'moderate', 'Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4.', 'DailyMed'),
(1584, 'benazepril', 'N/A', 'minor', 'Hyperkalemia otassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'potassium-cit', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride', 'DailyMed'),
(1584, 'esomeprazole sodium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(1584, 'ofloxacin', 'N/A', 'minor', 'Administration of quinolones with antacids containing calcium, magnesium, or aluminum, with sucralfate, with divalent or trivalent cations such as iron, or with multivitamins containing zinc or with didanosine, chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones resulting in systemic levels considerably lower than desired.', 'DailyMed'),
(1584, 'sodium chloride, potassium chloride, sodium lactate and calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringers Injection, USP should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(1584, 'milrinone lactate in dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom Milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(1584, 'deferasirox oral', 'N/A', 'moderate', 'Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(1584, 'esomeprazole  magnesium', 'N/A', 'minor', '( 7.1)  May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(1584, 'nabilone', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimeticagents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, otheranticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, othertricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium,opioids, buspirone, antihistamines, muscle relaxants,other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/oman who smoked marijuana; confirmed by dechallenge andrechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20mg/day fluoxetine X 4 wks became hypomanic aftersmoking ', 'DailyMed'),
(1584, 'sodium picosulfate, magnesium oxide and anhydrous citric acid', 'N/A', 'minor', ' Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions ( 7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid.', 'DailyMed'),
(1584, 'enalapril maleate oral solution', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'epinephrine', 'N/A', 'minor', 'Epinephrine is readily destroyed by alkalies and oxidizing agents (e.g., oxygen, chlorine, bromine, iodine, permanganates, chromates, nitrites, and salts of easily reducible metals, especially iron).', 'DailyMed'),
(1584, 'ioflupane i-123', 'N/A', 'minor', 'These potentially interfering drugs consist of: amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline. Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, modafinil norephedrine, phentermine, phenylpropanolamine, selegiline, sertraline, citalopram and paroxetine may interfere with Ioflupane I 123 Injection imaging.', 'DailyMed'),
(1584, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(1584, 'ferrous fumarate, folic acid', 'N/A', 'minor', 'Drug Interactions: Vitrexyl + iron is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine.', 'DailyMed'),
(1584, 'fosinopril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(1584, 'esomeprazole magnesium delayed release capsules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(1584, 'captopril and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(1584, 'ritonavir 100 mg', 'N/A', 'minor', 'Sedative/hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem  sedative/hypnotics A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(1584, 'raberprazole sodium d/r', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(1584, 'spironolactone and hydrochlorothiazide', 'N/A', 'moderate', 'Pressor Amines (e.g., norepinephrine) Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide. Therefore, when spironolactone and hydrochlorothiazide tablets and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(1584, 'ferumoxytol', 'N/A', 'minor', 'Feraheme may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(1584, 'sevelamer hydrochloride', 'N/A', 'major', 'Table 4: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly DigoxinEnalaprilIronMetoprololWarfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin.', 'DailyMed'),
(1584, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(1584, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(1584, 'sodium ferric gluconate complex in sucrose', 'N/A', 'minor', 'Sodium ferric gluconate complex in sucrose injection may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(1584, 'milrinone lactate in 5% dextrose', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(1584, 'polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate,  and sodium chloride for oral solution', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'omeprazole, clarithromycin, amoxicillin', 'N/A', 'minor', '(7.14) Omeprazole may interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, digoxin, and mycophenolate mofetil). As with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.', 'DailyMed'),
(1584, 'venlafaxine', 'N/A', 'minor', '] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'venlafaxine hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'carospir', 'N/A', 'severe', '7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1) Lithium: Increased risk of lithium toxicity (7.2) NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of CAROSPIR (7.3) Digoxin: CAROSPIR can interfere with radioimmunologic assays of digoxin exposure (7.4) Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5) Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone (7.6) 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of CAROSPIR with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. 7.4 Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin', 'DailyMed'),
(1584, 'doxyclycline hyclate', 'N/A', 'minor', '(7.2) Absorption of tetracyclines, including doxycycline hyclate tablets are impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. 7.3 Antacids and Iron Preparations Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(1584, 'valsartan/htcz', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'darunavir', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(1584, 'duloxetine hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'sodium sulfate, magnesium sulfate, and potassium chloride', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'duloxetine', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'citalopram hydrobromide', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'ferric maltol', 'N/A', 'minor', 'Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. 7.2 Effect of ACCRUFER on Other Drugs Dimercaprol Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity.', 'DailyMed'),
(1584, 'vilazodone hydrochloride', 'N/A', 'minor', 'Other Serotonergic Drugs Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'amlodipine, valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'escitslopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'enalapril', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(1584, 'darunavir ethanolate and cobicistat', 'N/A', 'moderate', 'Buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(1584, 'venlafaxine hydrochloride, extended release', 'N/A', 'moderate', '7.9 Monoamine Oxidase Inhibitors (MAOIs) [ See Dosage and Administration (2.6and 2.7), Contraindications (4.1), and Warnings and Precautions (5.2).] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'acetohydroxamic acid', 'N/A', 'minor', '(See Adverse Reactions.) AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may be reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.', 'DailyMed'),
(1584, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'darunavir 600 mg', 'N/A', 'contraindicated', 'Buspirone, diazepam, estazolam, zolpidem parenterally administered midazolam  midazolam  triazolam  sedatives/hypnotics Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.', 'DailyMed'),
(1584, 'carbidopa levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of DHIVY ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with DHIVY is contraindicated [see Contraindications (4) ]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and carbidopa and can cause a reduction in the bioavailability of DHIVY. If iron salts or multivitamins containing iron salts are co-administered with DHIVY, monitor patients for worsening Parkinsons symptoms.', 'DailyMed'),
(1584, 'omeprazole magnesium', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'escitalopram oxalate', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram oxalate and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'sacubitril and valsartan', 'N/A', 'moderate', '7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].', 'DailyMed'),
(1584, 'sodium sulfate, potassium sulfate and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'escitalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'venofer (iron sucrose)', 'N/A', 'minor', '7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(1584, 'sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'moderate', 'Because of its potassium content, Lactated Ringer''s Injection should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(1584, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives SucralfateBuffered medications  BIC Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing calcium or iron is not recommended.', 'DailyMed'),
(1584, 'citalopram', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'fluvoxamine maleate', 'N/A', 'minor', 'Other Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'fluoxetine hcl', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'omeprazole magnesium, amoxicillin and rifabutin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact Omeprazole can alter the absorption of other drugs due to its effect of reducing intragastric acidity thereby increasing gastric pH.', 'DailyMed'),
(1584, 'sertraline hcl', 'N/A', 'minor', 'Examples: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'llevofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR and watch for bleeding ( 7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with ', 'DailyMed'),
(1584, 'sarecycline hydrochloride', 'N/A', 'minor', '( 5.4, 7.1 ) Antacids and iron preparations: separate dosing of SEYSARA. Antacids and Iron Preparations Coadministration with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations may impair absorption of SEYSARA, similar to other tetracyclines, which may decrease its efficacy. Separate dosing of SEYSARA from antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations.', 'DailyMed'),
(1584, 'levomilnacipran', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Metabolized by CYP3A: e.g., buspirone, diazepam, estazolam, zolpidem  sedatives/hypnotics With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.', 'DailyMed'),
(1584, 'bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(1584, 'pantoprazole sodium delayed-release', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'milnacipran hcl', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'omeprazole/sodiium bicarbonate', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(1584, 'lansoprazole dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'ciprofolxacin', 'N/A', 'minor', 'Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].', 'DailyMed'),
(1584, 'pentosan polysulfate sodium', 'N/A', 'moderate', 'See also PRECAUTIONSon the use of ELMIRON in patients receiving other therapies with anticoagulant effects.', 'DailyMed'),
(1584, 'demeclocycline', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations.', 'DailyMed'),
(1584, 'duloxetin hydrochloride', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'carbidopa, levodopa, and entacapone', 'N/A', 'moderate', '7 DRUG INTERACTIONS Drugs metabolized by COMT: use with caution (5.11,7.2) Anti-hypertensive agents: dose adjustment may be required (7.3) Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa (7.4) Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Stalevo (7.5, 7.6, 7.7, 7.8, 7.9) Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Stalevo may be required (7.10) Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Stalevo may be required; monitor INR when initiating Stalevo in patients on coumadin (7.11) 7.1 MAO Inhibitors Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and', 'DailyMed'),
(1584, 'vitamin c, zinc, arnica montana extract, bromelain,  diosmin,  rutin,  citrus bioflavonoids, hesperidin methyl chalcone', 'N/A', 'minor', 'High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements.', 'DailyMed'),
(1584, 'carbidopa tablets, 25 mg', 'N/A', 'moderate', 'Carbidopa Tablets and iron salts or multi vitamins containing iron salts should be co administered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.', 'DailyMed'),
(1584, 'iron dextran', 'N/A', 'minor', 'Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Serum iron determinations (especially by colorimetric assays) may not be meaningful for 3 weeks following the administration of INFeD.', 'DailyMed'),
(1584, 'iron, folate', 'N/A', 'minor', 'Drug Interactions: Davimet with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine.', 'DailyMed'),
(1584, 'esomeprazole', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(1584, 'olanzapine and fuoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'levodopa', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Monitor patients on MAO-B inhibitors for orthostatic hypotension ( 7.1) Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2, 7.3) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4)]. 7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.', 'DailyMed'),
(1584, 'vadadustat', 'N/A', 'minor', '7 DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. (7.1) Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of VAFSEO.', 'DailyMed'),
(1584, 'potassium chloride oral', 'N/A', 'minor', '7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(1584, 'paroxetine hydrochloride hemihydrate', 'N/A', 'minor', 'Examples other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'ciprofloxacin tablets', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx  (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration ( 2.4)].', 'DailyMed'),
(1584, 'ciprofloxacin hcl', 'N/A', 'minor', 'Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see DOSAGE AND ADMINISTRATION (2.4)].', 'DailyMed'),
(1584, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'amlodipine,valsartan and hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(1584, 'pantoprazole sodium dr', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'esomeprazole dr', 'N/A', 'minor', 'Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.', 'DailyMed'),
(1584, 'methylene blue', 'N/A', 'contraindicated', 'Avoid concomitant use of methylene blue injection with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.', 'DailyMed'),
(1584, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'moderate', 'Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitaminscation-containing antacids or laxativessucralfatebuffered medications  elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. buspironezolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(1584, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'cosyntropin', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(1584, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan -adrenoceptor blockers (-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(1584, 'selegiline', 'N/A', 'moderate', '(Bottled and canned beers and wines contain little or no tyramine.) Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewers yeast, bakers yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine 7.3 Sympathomimetic Amines and Buspirone The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure. Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).', 'DailyMed'),
(1584, '.beta.-carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium pantothenate, calcium carbonate, ferrous fumarate, zinc oxide and docusate sodium', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(1584, 'duloxetine d/r', 'N/A', 'minor', '7.14 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'lansoprazole, amoxicillin, clarithromycin', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'escitalopram oral', 'N/A', 'minor', 'Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'milnacipran hydrochloride', 'N/A', 'minor', '7.2 Serotonergic Drugs Serotonin syndrome can occur with use of SAVELLA and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'vortioxetine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'vitamins and minerals', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(1584, 'sodium sulfate, potassium sulfate and magnesium sulfate oral', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'ziprasidone mesylate', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'pantoprazole sodium granules', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'pantoprazole sodium injection', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.', 'DailyMed'),
(1584, 'sodium picosulfate, magnesium oxide, and anhydrous citric acid', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3)], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'omadacycline', 'N/A', 'minor', '( 7.1) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1)].', 'DailyMed'),
(1584, 'olanzapine and fluoxetine', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'amlodipine besylate valsartan hydrochlorothiazide', 'N/A', 'minor', 'Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(1584, 'ziprasidone hcl', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(1584, 'ziprasidone hydrochloride', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opiods, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'minocycline hydrochloride extended-release', 'N/A', 'minor', '7.3 Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.', 'DailyMed'),
(1584, 'multivitamin/mineral', 'N/A', 'minor', 'DRUG INTERACTIONS Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.', 'DailyMed'),
(1584, 'leucine, phenylalanine, lysine, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, serine, tyrosine, sodium acetate, dibasic potassium phosphate, magnesium chloride, sodium chloride, calcium chloride, dextrose', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Drugs that Can Cause Hyperkalemia Because of its potassium content, CLINIMIX E should be administered with caution in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(1584, 'eltrombopag olamine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(1584, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(1584, 'atazanavir and cobicistat', 'N/A', 'moderate', 'Other Sedatives/Hypnotics: buspirone, zolpidem With other sedatives/hypnotics that are CYP3A metabolized, a dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(1584, 'sodium chloride, soldium lactate, potassium chloride and calcium chloride', 'N/A', 'minor', 'The risk of hyperkalemia is increased in patients treated with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium-sparing diuretics (amiloride, spironolactone, triameterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.', 'DailyMed'),
(1584, 'valsartan oral', 'N/A', 'minor', '7 DRUG INTERACTIONS Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7) NSAIDs increase risk of renal impairment and loss of antihypertensive effect ( 7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium- sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., h', 'DailyMed'),
(1584, 'cortrosyn', 'N/A', 'minor', 'Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Drug effects on plasma cortisol levels:  Accuracy of the test results can be affected by concomitant medications. Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels.', 'DailyMed'),
(1584, 'trientine tetrahydrochloride', 'N/A', 'minor', 'Iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable (2.2, 7.1): Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR.', 'DailyMed'),
(1584, 'potassium chloride for oral solution', 'N/A', 'minor', '7.2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(1584, 'nirmatrelvir and ritonavir', 'N/A', 'moderate', 'Sedative/hypnotics buspirone,clorazepate,diazepam,estazolam,flurazepam,zolpidem  sedative/hypnotic A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.', 'DailyMed'),
(1584, 'cobicistat', 'N/A', 'moderate', 'Buspironezolpidem With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.', 'DailyMed'),
(1584, 'sodium sulfate, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'vonoprazan fumarate and amoxicillin', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness. Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(1584, 'sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate', 'N/A', 'minor', 'Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.', 'DailyMed'),
(1584, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or iron a Dolutegravir When taken with food, TRIUMEQ or TRIUMEQ PD and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, TRIUMEQ or TRIUMEQ PD should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(1584, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or irona Dolutegravir When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.', 'DailyMed'),
(1584, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', 'Oral calcium and iron supplements, including multivitamins containing calcium or ironb (non-antacid) Dolutegravir Administer JULUCA and supplements containing calcium or iron together with a meal or take JULUCA 4 hours before or 6 hours after taking these supplements.', 'DailyMed'),
(1584, 'eltrombopag', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.', 'DailyMed'),
(1584, 'delafloxacin meglumine', 'N/A', 'minor', 'Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1584, 'levoketoconazole', 'N/A', 'minor', 'Examples Alfentanil, avanafil, buspirone, conivaptan b, dabigatran etexilate, darifenacin, darunavir, digoxin, ebastine, everolimus, fexofenadine, ibrutinib, lomitapide, lovastatin, lurasidone, midazolam, naloxegol, nisoldipine, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir b, triazolam, and vardenafil.', 'DailyMed'),
(1584, 'ziprasidone', 'N/A', 'minor', 'Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(1584, 'alprazolam odt c-iv', 'N/A', 'minor', '7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(1584, 'technetium tc 99m medronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(1584, 'mitotane', 'N/A', 'minor', '7 DRUG INTERACTIONS Spironolactone:Avoid concomitant use with LYSODREN. ( 7.2) 7.1 Effects of Other Drugs on LYSODREN Spironolactone Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(1584, 'metyrapone', 'N/A', 'minor', '( 7.1) Acetaminophen: Avoid concomitant use with Metopirone. ( 7.2) 7.1 Effect of Other Drugs on Metopirone Anticonvulsants, psychotropic drugs, hormone preparations, corticosteroids, antithyroid agents and cyproheptadine may affect the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.', 'DailyMed'),
(1584, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride', 'N/A', 'minor', '7.6 Antacids, Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(1584, 'vonoprazan fumarate', 'N/A', 'minor', 'Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2)], which may decrease the absorption of drugs reducing their effectiveness.', 'DailyMed'),
(1584, 'levomilnacipran hydrochloride', 'N/A', 'minor', 'Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(1584, 'sodium ferric gluconate complex', 'N/A', 'minor', 'Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations.', 'DailyMed'),
(1584, 'technetium tc 99m pyrophosphate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(1584, 'technetium tc 99m oxidronate', 'N/A', 'minor', 'Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).', 'DailyMed'),
(31818, 'trovafloxacin mesylate', 'N/A', 'major', 'Drug Interactions Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions).', 'DailyMed'),
(31818, 'torsemide', 'N/A', 'major', 'In healthy subjects, coadministration of DEMADEX was associated with significant reduction in the renal clearance of spironolactone, with corresponding increases in the AUC. This effect has been demonstrated for DEMADEX under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day).The pharmacokinetic profile and diuretic activity of torsemide are not altered by cimetidine or spironolactone.', 'DailyMed'),
(31818, 'doxycycline', 'N/A', 'contraindicated', 'Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracycline may render oral contraceptives less effective.', 'DailyMed'),
(31818, 'omeprazole, sodium bicarbonate and magnesium hydroxide', 'N/A', 'major', 'Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(31818, 'minocycline hydrochloride', 'N/A', 'contraindicated', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.', 'DailyMed'),
(31818, 'doxycycline hyclate', 'N/A', 'minor', 'Drug interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.', 'DailyMed'),
(31818, 'lisinopril and hydrochlorothiazide', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'carbidopa and levodopa', 'N/A', 'moderate', 'Patients taking these drugs with PARCOPA should be carefully observed for loss of therapeutic response.Iron salts may reduce the bioavailability of levodopa and carbidopa.', 'DailyMed'),
(31818, 'buspirone hydrochloride', 'N/A', 'major', 'Drug Interactions Psychotropic AgentsMAO Inhibitors: It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors (see WARNINGS section).Amitriptyline: After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.Diazepam: After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.Haloperidol: In a study in normal vol', 'DailyMed'),
(31818, 'benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'enalaprilat', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'ferumoxides', 'N/A', 'minor', 'Administration provides elemental iron. In patients who are receiving supplemental iron orally or parenterally, the dose of supplemental iron may need to be decreased.The effect of concomitant parenteral iron on Feridex I.V.', 'DailyMed'),
(31818, 'enalapril maleate', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'ramipril', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'gemifloxacin mesylate', 'N/A', 'minor', 'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.', 'DailyMed'),
(31818, 'fosinopril sodium and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'nefazodone hydrochloride', 'N/A', 'major', 'Therefore, dosage adjustment is not necessary for either drug when coadministered.Triazolam/AlprazolamSee CONTRAINDICATIONS and WARNINGS.AlcoholAlthough nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of nefazodone and alcohol in depressed patients is not advised.BuspironeIn a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in C max and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of buspirone, sligh', 'DailyMed'),
(31818, 'omeprazole', 'N/A', 'major', '7 DRUG INTERACTIONS Drugs for which gastric pH can affect bioavailability Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole delayed-release capsules may interfere with absorption due to inhibition of gastric acid secretion (7) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole delayed-release capsules can prolong their elimination.', 'DailyMed'),
(31818, 'quinapril', 'N/A', 'moderate', 'If concomitant therapy of quinaprilhydrochloride with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride),potassium supplements, or potassium-containing salt substitutes is indicated, they should be usedwith caution along with appropriate monitoring of serum potassium (see PRECAUTIONS).', 'DailyMed'),
(31818, 'felodipine', 'N/A', 'major', 'Other Concomitant Therapy In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.', 'DailyMed'),
(31818, 'ciprofloxacin hydrochloride', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(31818, 'lisinopril', 'N/A', 'major', 'Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone,eplerenone,triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'moxifloxacin hydrochloride', 'N/A', 'minor', 'Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(31818, 'pantoprazole sodium', 'N/A', 'major', 'Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(31818, 'perindopril erbumine', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'dexlansoprazole', 'N/A', 'major', 'It is theoretically possible that KAPIDEX may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(31818, 'tetracycline hydrochloride', 'N/A', 'minor', 'Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.', 'DailyMed'),
(31818, 'spironolactone', 'N/A', 'moderate', 'Pressor Amines (eg, Norepinephrine):Spironolactone reduces the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone. Therefore, when spironolactone and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.', 'DailyMed'),
(31818, 'ciprofloxacin', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired.', 'DailyMed'),
(31818, 'trandolapril', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'warfarin sodium', 'N/A', 'minor', 'Alcoholaminoglutethimideamobarbitalatorvastatinazathioprinebutabarbitalbutalbitalcarbamazepinechloral hydratechlordiazepoxidechlorthalidone cholestyramineclozapinecorticotropincortisonecyclophosphamidedicloxacillinethchlorvynolglutethimidegriseofulvinhaloperidolmeprobamate 6-mercaptopurinemethimazolemoricizine hydrochloridenafcillinparaldehydepentobarbitalphenobarbitalphenytoinpravastatinprednisoneprimidone propylthiouracilraloxifeneranitidinerifampinsecobarbitalspironolactonesucralfatetrazodonevitamin C (high dose)vitamin Kwarfarin underdosage Because a patient may be exposed to a combination of the above factors, the net effect of warfarin sodium on PT/INR response may be unpredictable.', 'DailyMed'),
(31818, 'digoxin', 'N/A', 'minor', 'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digox-in concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.', 'DailyMed'),
(31818, 'cefdinir', 'N/A', 'minor', 'Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.', 'DailyMed'),
(31818, 'esomeprazole magnesium', 'N/A', 'major', '7 DRUG INTERACTIONS May affect plasma levels of antiretroviral drugs  use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, and digoxin) (7.2) Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3) May increase systemic exposure of cilostazol and an active metabolite. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, atazanavir, iron salts, and digoxin).', 'DailyMed'),
(31818, 'diltiazem hydrochloride', 'N/A', 'major', 'Buspirone. In nine healthy subjects, diltiazem significantly increased the mean buspirone 5.5-fold and Cmax 4.1-fold compared to placebo. The T and Tmax of buspirone were not significantly affected by diltiazem.', 'DailyMed'),
(31818, 'lansoprazole', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(31818, 'ibandronate sodium', 'N/A', 'minor', '(7.2) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of BONIVA.', 'DailyMed'),
(31818, 'captopril', 'N/A', 'major', 'Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.', 'DailyMed'),
(31818, 'enalapril maleate and hydrochlorothiazide', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'rabeprazole sodium', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(31818, 'losartan potassium and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).', 'DailyMed'),
(31818, 'amlobenz', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'lovastatin', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.', 'DailyMed'),
(31818, 'topiramate', 'N/A', 'minor', 'Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.', 'DailyMed'),
(31818, 'bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)', 'N/A', 'minor', '7.7 Antacids, Multivitamins, or Dairy Products The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.', 'DailyMed'),
(31818, 'potassium citrate', 'N/A', 'severe', '7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) 7.1 Potential Effects of Potassium citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of Urocit-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.', 'DailyMed'),
(31818, 'lansoprazole, amoxicillin and clarithromycin', 'N/A', 'major', 'It is theoretically possible that PREVACID may also interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed'),
(31818, 'lidocaine hydrochloride', 'N/A', 'minor', 'Drug Interactions: This section will be deleted in the development environment.', 'DailyMed'),
(31818, 'alprazolam', 'N/A', 'minor', 'Drugs Effecting Salivary Flow and Stomach pH Because NIRAVAM disintegrates in the presence of saliva and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.', 'DailyMed'),
(31818, 'levofloxacin', 'N/A', 'moderate', 'Monitor prothrombin time, INR, watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.10, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins LEVAQUIN Tablets and Oral Solution While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc o', 'DailyMed'),
(31818, 'pantoprazoel sodium', 'N/A', 'major', 'Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).', 'DailyMed'),
(31818, 'ciprofloxacin hydrochloride   tablet', 'N/A', 'minor', 'Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired (see DOSAGE AND ADMINISTRATION for concurrent administration of these agents with ciprofloxacin).', 'DailyMed'),
(31818, 'valsartan', 'N/A', 'minor', 'Spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(31818, 'lisinopril, arginine', 'N/A', 'major', 'Use of Lisinopril Tablets with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(31818, 'naproxen and esomeprazole magnesium', 'N/A', 'major', 'Monitor for increases in INR and prothrombin time (7.7)  Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin) Patients treated with VIMOVO and digoxin may need to be monitored for increases in digoxin toxicity (7.12)  As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of nephrotoxicity. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).', 'DailyMed'),
(31818, 'amlodipine besylate and benazepril hydrochloride', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'losartan potassium', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.', 'DailyMed'),
(31818, 'milrinone lactate', 'N/A', 'minor', 'Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.', 'DailyMed'),
(31818, 'amlodipine valsartan and hydrochlorothiazide', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(31818, 'eprosartan mesylate and hydrochlorothiazide', 'N/A', 'moderate', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements ).', 'DailyMed'),
(31818, 'amlodipine besylate and valsartan', 'N/A', 'minor', 'As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.', 'DailyMed'),
(31818, 'dronabinol', 'N/A', 'minor', 'CONCOMITANT DRUG CLINICAL EFFECT(S) Amphetamines, cocaine, other sympathomimetic agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine, scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness Amitriptyline, amoxapine, desipramine, other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disulfiram A reversible hypomanic reaction was reported in a 28 y/o man who smoked marijuana; confirmed by dechallenge and rechallenge Fluoxetine A 21 y/o female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks became hypomanic after', 'DailyMed'),
(31818, 'trandolapril and verapamil hydrochloride', 'N/A', 'minor', 'Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Tranquilizers/ Anti-depressants Due to metabolism via the CYP enzyme system, there have been reports that verapamil may increase the concentrations of buspirone, midazolam, almotriptan and imipramine.', 'DailyMed'),
(31818, 'benazepril hydrochloride and hydrochlorothiazide', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31818, 'pravastatin sodium', 'N/A', 'moderate', 'Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.', 'DailyMed'),
(31818, 'anagrelide hydrochloride', 'N/A', 'minor', 'Drug interaction studies have not been conducted with the other common medications used concomitantly with anagrelide in clinical trials which were acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.', 'DailyMed');

